XGENOMES CORP.
Biotech · Private
Direct DNA methylation sequencing platform using novel conversion chemistry and sequencing technology
xgenomes.com →- Grants
- $2.3M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 16
- 3 granted · 13 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Authenticating and Monitoring Cell Lines Using Single Molecule Genomics | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Authenticating and Monitoring Cell Lines Using Single Molecule Genomics | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Super-Resolution Sequencing on a DNA Lattice | $280,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Super-resolution single-molecule sequencing by observing the dynamic hybridization of a repertoire of oligonucleotides to DNA targets | $384,418 | |
| Federal grant | Department of Health and Human Services · Phase I · Sequencing of epigenetic modifications across the genome by single-molecule detection of oligonucleotide binding kinetics | $397,599 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel ctDNA analysis solution for the next-generation of liquid biopsy assays | $399,816 | |
| Federal grant | Department of Health and Human Services · Phase I · Achieving ultra-high-density, ultra-high-precision single molecule localization microscopy with whole-video deep learning architectures | $349,280 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1117 | NUTRASORB LLC | — | — |
| 1118 | FGF Therapeutics INC. | — | — |
| 1119 | DURAVAX INC | — | — |
| 1120 | XGENOMES CORP. | — | — |
| 1121 | LYTICON, LLC | — | — |
| 1122 | Sana Biotechnology | — | $867M |
| 1123 | Walden Biosciences | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Random Epigenomic Samplingapplication
- Sequencing By Emergenceapplication
- Systems And Methods For Determining Sequenceapplication
- Sequencing By Emergencegranted
- Sequencing By Coalescenceapplication
- Sequencing By Emergenceapplication
- Sequencing By Emergencegranted
- Molecular Identification With Subnanometer Localization Accuracygranted
- Systems And Methods For Determining Sequenceapplication
- Sequencing By Coalascenceapplication
- Sequencing By Emergenceapplication
- Systems, Methods, And Compositions For Detecting Epigenetic Modifications Of Nucleic Acidsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.